NASDAQ · Financial Statements
Akero Therapeutics, Inc. (AKRO) Financial Statements
$54.65
NASDAQ: AKRO
Market Cap $4.50B
Overview Financials Dividend Akero Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-252.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2023 2024 Revenue $0 $0 $0 $0 $0 Operating Profit $-80.0M $-101.0M $-115.0M $-173.0M $-285.0M Net Profit $-79.0M $-101.0M $-112.0M $-152.0M $-252.0M EPS $-2.52 $-2.89 $-2.87 $-2.89 $-3.75 Op Margin — — — — —
Balance Sheet (USD)
Metric 2020 2021 2022 2023 2024 Total Assets $273.0M $196.0M $357.0M $580.0M $826.0M Total Liabilities $15.0M $26.0M $30.0M $45.0M $76.0M Cash $187.0M $150.0M $250.0M $234.0M $340.0M Borrowings $2.0M $2.0M $11.0M $26.0M $36.0M
Cash Flow (USD)
Metric 2020 2021 2022 2023 2024 Operating Cash Flow $-71.0M $-80.0M $-93.0M $-145.0M $-230.0M Investing Cash Flow $-10.0M $42.0M $-64.0M $-224.0M $-111.0M Financing Cash Flow $1.0M $0 $4.0M $3.0M $13.0M Net Cash Flow $123.0M $-37.0M $99.0M $-16.0M $106.0M Free Cash Flow $-71.0M $-80.0M $-93.0M $-145.0M $-231.0M
Valuation & Return Ratios
Metric Value PEG Ratio -88.50 EV / EBITDA -19.71 FCF Yield -4.07% Quick Ratio 15.83 Interest Coverage -73.72 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock